Amicus Therapeutics: A Biotech Stock Facing Divergent Views

Shares of Amicus Therapeutics (FOLD) edged higher on Friday, closing at $7.61 to secure a modest gain of 0.13%. This advance extended the stock’s recent positive momentum, marking its third consecutive day of gains and a cumulative increase of over 12% across a two-week span. Notably, the recent uptick was accompanied by trading volume that exceeded the average, a development often interpreted by technical analysts as a bullish indicator.

Wall Street’s Mixed Signals

Market experts on Wall Street maintain a “Moderate Buy” consensus rating on the biopharmaceutical company. Among the analysts covering the stock, eight recommend a Buy, while two advise holding the position. The average price target of $16.22 suggests a potential upside of more than 113% from current levels.

However, a closer look reveals significant divergence in their assessments. In a notable contrast of opinion, UBS raised its price target to $22.00 in May. Simultaneously, Goldman Sachs maintained a “Neutral” rating but revised its target down to $9.00. More recently in mid-July, Morgan Stanley upgraded the stock to an “Overweight” rating.

Major Investors Take Conflicting Actions

Substantial portfolio adjustments are underway behind the scenes among major institutional investors, highlighting a clear lack of consensus on the company’s future trajectory.

Should investors sell immediately? Or is it worth buying Amicus Therapeutics?

• PNC Financial Services aggressively increased its stake by 211.4%.
• GAMMA Investing executed a massive purchase, boosting its position by a remarkable 1,610.8%.
• Osterweis Capital Management established a new position valued at $6.73 million.

These bullish moves were countered by Fox Run Management, which reduced its holding by 65.7% during the first quarter.

Strong Revenue Growth Amid Path to Profitability

For the second quarter of 2025, Amicus reported solid financial results. Total revenue reached $154.7 million, which represents an 18% year-over-year increase after adjusting for currency effects. This growth was driven by two key products:

• Galafold: Sales grew 12% to $128.9 million.
• Pombiliti + Opfolda: This combination therapy saw a sharp 58% increase in revenue, reaching $25.8 million.

Despite this robust operational performance, the company posted a GAAP net loss of $24.4 million. This figure was significantly impacted by a one-time $30 million payment related to the licensing of DMX-200. When excluding this and other special items, Amicus actually achieved an adjusted profit of $1.9 million.

Management reaffirmed its full-year 2025 guidance and anticipates reaching GAAP profitability in the second half of the year. The company’s long-term ambition is to achieve $1 billion in annual revenue by 2028. A critical milestone is the ongoing Phase 3 study for DMX-200 in FSGS, which is expected to complete patient recruitment by the end of this year.